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Table 1. Angiographic, IVUS and Clinical Results
DESyne Endeavor p-value
Angiographic Results
Baseline RVD (post-procedure) 3.000.37 3.080.35 0.21
6-month angiographic/IVUS
In-stent Late Lumen Loss 0.120.15 0.670.47 < 0.001
% neointimal volume 3.64.2 20.714.2 <0.001
Clinical Results
6-month DoCE (%) 2.7 3.2 1
Clinically-indicated TLR 1.8 3.2 0.52
12-month DoCE (%) 2.7 3.2 1
Clinically-indicated TLR 1.8 3.2 0.52
24-month DoCE (%) 2.7 3.2 1
Clinically-indicated TLR 1.8 3.2 0.52
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: The DESyne BD NECSS demonstrated non-inferiority and superi-
ority over Endeavor for in-stent late lumen loss at 6 months. Clinical events
remained low through 24 months; clinical results through 36 months will be
presented.
TCT-587
What if current generation drug-eluting stents were used in the SYNTAX trial?
Analysis of the COMPARE and SYNTAX trials 5 year follow-up
Pieter C. Smits1, Georgios J. Vlachojannis2, Vasim Farooq3, Patrick W. Serruys4
1Maasstad Hospital Rotterdam, Rotterdam, Netherlands, 2Maasstad Hospital,
Rotterdam, Netherlands, 3Manchester Royal Infirmary/ThoraxCenter Rotterdam,
Rotterdam, Netherlands, 4Thoraxcenter, Rotterdam, MD
Background: The SYNTAX trial represents the most comprehensive comparison of
percutaneous coronary intervention (PCI) and coronary artery bypass grafting
(CABG). Newer generation everolimus-eluting stents (Xience V; EES) have how-
ever been shown to have superior efficacy and safety profile compared to first gen-
eration paclitaxel-eluting stents (Taxus Liberté; PES) used in the SYNTAX trial. As
to whether outcomes in the SYNTAX trial would have changed using the newer
generation EES is unsettled.
Methods: COMPARE is a prospective, randomized, single-center, all-comer trial
comparing EES to PES (1:1). As of present is the only randomized trial comparing
EES to PES in an all-comers population, which included complex multi-vessel (MV)
and/or left main (LM) disease, and had an independent adjudicated 5-year follow-up.
To mirror the SYNTAX population, a sub-analysis of COMPARE was performed in
subjects undergoing PCI for MV and/or LM disease (n¼466; 234 treated with PES
and 232 with EES). For both trials identical adjudicated composite endpoint major
adverse cardiac events (MACE: death, myocardial infarction, or target vessel revas-
cularization) were used at 5 years. Results were stratified by anatomical complexity
using the SYNTAX score.
Results: The incidence of MACE in COMPARE and SYNTAX with EES, PES or
CABG are tabulated.SYNTAX score COMPARE trial
MACE (%)
SYNTAX trial
MACE (%)
PES
(n¼234)
EES
(n¼232)
PES
(n¼871)
CABG
(n¼805)
<23 (low) 29.5 18.0 30.8 24.7
23-32 (intermediate) 40.9 18.6 34.3 22.1
‡33 (high) 45.5 36.4 42.2 22.4Conclusions: The results of this analysis suggest that in subjects with MV and/or
LM disease, newer generation EES might be superior to CABG in patients with low
SYNTAX score, and equivalent in intermediate SYNTAX score, latter group
currently recommended for CABG. Only the high SYNTAX score group showed a
clear long-term benefit of CABG over PCI irrespective of stent type used. Newer
generation drug eluting stents may allow for further refinement of the boundaries
between PCI and CABG, which may have important clinical and economical
implications.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteTCT-588
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Background: The multicenter, prospective, randomized, single-blinded, investigator-
initiated DUTCH PEERS (TWENTE II) “All Comers” Trial demonstrated at 1-year
follow-up the non-inferiority of third-generation Resolute Integrity zotarolimus-
eluting stents (Medtronic Vascular, Santa Rosa, CA) versus Promus Element ever-
olimus-eluting stents (Boston Scientific, Natick, MA), based on a similar incidence of
the primary endpoint target vessel failure (TVF), a composite of cardiac death, target
vessel revascularization (TVR), or myocardial infarction (MI). No other follow-up
data beyond 12 months have been published from a randomized head-to-head com-
parison of both stents.
Methods: In 4 study centers in the Netherlands, 1,811 patients were 1:1 randomly
assigned to treatment with one of both stents. Patients with any clinical syndrome, any
lesion type, and any number of lesions or vessels to be treated were included. Study
monitoring and clinical event adjudication were performed by two independent Dutch
contract research organizations (Diagram, Zwolle, and Cardialysis, Rotterdam,
respectively).
Results: DUTCH PEERS examines an all-comer patient population that included 59%
of patients with acute coronary syndromes (20% of all patients presented with an acute
STEMI) and 66% of patients with complex target lesions. We will compare for both
stent groups the 2-year incidence of TVF (primary endpoint) and various secondary
endpoints, including individual components of the primary endpoint, the incidence of
stent thrombosis, and other composite endpoints, such as target lesion failure, major
adverse cardiac events, and the patient-oriented composite endpoint. In addition, we
will report the outcome of patients with longitudinal stent deformation after discon-
tinuation of dual anti-platelet therapy.
Conclusions: Clinical outcome of the DUTCH PEERS trial at 2-year follow-up will
be presented.
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Background: Long-term comparison data of the current generation everolimus-
eluting stent (Xience V; EES) with the first generation paclitaxel-eluting stent
(Taxus Liberté; PES) in an all-comers diabetic cohort undergoing percutaneous
coronary intervention (PCI) are scarce. Initial results at 2 year follow-up indi-
cated no differences in clinical outcomes between the two stent types in diabetic
patients.
Methods: The COMPARE I study was a prospective, randomized, single-center, all-
comer trial randomly allocating (1:1) patients to receive either EES or PES. It is to
date the only randomized trial comparing EES to PES in a true all-comers popu-
lation with an independent adjudicated 5-year follow-up. Randomization was strat-
ified by the presence of diabetes. The primary endpoint was major adverse
cardiovascular events (MACE) defined as the composite of the safety endpoints
death or myocardial infarction (MI) and the efficacy endpoint target vessel revas-
cularization (TVR).
Results: Of the 1800 study patients, 325 patients were diabetic (18.1%) of whom 153
were treated with EES and 172 with PES. At 5 years EES reduced MACE compared
to PES in non-diabetic patients (17.1% vs. 23.0%, p< 0.01) with significant reduction
in MI (6.6% vs. 11.1%, p< 0.01), TVR (7.0% vs. 10.4%, p¼0.02), and definite or
probable stent thrombosis (2.6% vs. 5.5%, p< 0.01). In the diabetic patients, EES
compared to PES reduced MACE (24.8% vs. 34.3%, p¼0.06) and TVR (9.2% vs.
15.7%, p¼0.08) without reaching statistical significance. The 5 year outcomes are
tabulated.nts - Drug-eluting: Randomized Trials B171
